Pfizer Inc (PFE)

[DewDiligence]

FDA approves PFE’s Vizimpro (dacomitinib) for NSCLC with specified EGFR mutations:

https://finance.yahoo.com/news/u-fda-approves-vizimpro-dacomitinib-214100879.html

Pfizer today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

PFE rarely if ever talks about this drug, so it’s probably not going to be a needle-mover.